Dignitana AB Publishes Q3 2021 Interim Report
Moving toward cash flow positivity in 2022 with accelerating reimbursement activityFinancial highlights Q3 2021 · Net sales amounted to 13,7 MSEK (10.9), an increase of 25 percent over the same period 2020. · Operating result amounted to -13.6 MSEK (-9,5) · Net result after financial items amounted to -13.9 MSEK (-9.9) · Earnings per share were -0,21 SEK (-0,18) · Cash Balance amounted to 21.0 MSEK (14.8) · Average Daily Treatment Revenue (ADTR)* was 147 TSEK (99), an increase of 47 percent over the same period in 2020. Financial highlights January – September 2021